Oncology Institute (TOI) CMO sells 23,451 shares under 10b5-1 plan

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Oncology Institute, Inc. Chief Medical Officer Yale Podnos reported an open-market sale of 23,451 shares of common stock on June 8, 2026 at a volume-weighted average price of $5.3769 per share. After this transaction, he continues to hold 259,527 shares directly. The filing notes the sale prices ranged from $5.35 to $5.42 and that the trades were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on August 26, 2025.

Insider Trade Summary 10b5-1

Net Seller: 23,451 shares ($126,094)

Net Sell 1 txn

Insider Podnos Yale

Role Chief Medical Officer

Sold 23,451 shs ($126K)

Type	Security	Shares	Price	Value
Sale	Common Stock	23,451	$5.3769	$126K

Holdings After Transaction: Common Stock — 259,527 shares (Direct, null)

Footnotes (1)

Price is the volume weighted average selling price of all sales on behalf of the Reporting Person on June 8, 2028 within a one-dollar range. Actual prices ranged from $5.35 to $5.42. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price. Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan that was adopted on 08/26/2025.

Key Figures

Shares sold: 23,451 shares Average sale price: $5.3769 per share Price range: $5.35–$5.42 per share +2 more

5 metrics

Shares sold 23,451 shares Open-market sale of common stock on June 8, 2026

Average sale price $5.3769 per share Volume-weighted average price for June 8, 2026 sales

Price range $5.35–$5.42 per share Actual trade prices on June 8, 2026

Shares held after transaction 259,527 shares Direct ownership after reported sale

Trading plan adoption date August 26, 2025 Rule 10b5-1(c) plan governing the sales

Key Terms

Rule 10b5-1(c) plan, volume weighted average selling price, open-market sale, Form 4

4 terms

Rule 10b5-1(c) plan regulatory

"Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan"

volume weighted average selling price financial

"Price is the volume weighted average selling price of all sales"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/09/2026 - 07:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Podnos Yale

(Last)

(First)

(Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS

CALIFORNIA

90703

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/08/2026		S⁽¹⁾⁽²⁾		23,451	D	$5.3769	259,527	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Price is the volume weighted average selling price of all sales on behalf of the Reporting Person on June 8, 2028 within a one-dollar range. Actual prices ranged from $5.35 to $5.42. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

2. Sales were made on behalf of the Reporting Person pursuant to the Rule 10b5-1(c) plan that was adopted on 08/26/2025.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Yale Podnos	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did TOI Chief Medical Officer Yale Podnos report?

Yale Podnos reported selling 23,451 shares of Oncology Institute common stock in an open-market transaction. The sale occurred on June 8, 2026 at a volume-weighted average price of $5.3769 per share, according to the Form 4 filing.

At what price did Yale Podnos sell TOI shares in this Form 4 filing?

The reported volume-weighted average sale price was $5.3769 per share. Footnotes explain that actual sale prices on June 8, 2026 ranged from $5.35 to $5.42 per share, reflecting multiple trades within that one-dollar price band.

How many Oncology Institute (TOI) shares does Yale Podnos hold after the sale?

Following the reported transaction, Yale Podnos directly holds 259,527 shares of Oncology Institute common stock. This post-transaction balance is disclosed in the Form 4 and reflects his remaining direct ownership after the 23,451-share sale.

Was the TOI insider sale by Yale Podnos made under a Rule 10b5-1 plan?

Yes. The filing states the sales were made on behalf of Yale Podnos pursuant to a Rule 10b5-1(c) trading plan. That plan was adopted on August 26, 2025, indicating the trades were pre-arranged rather than discretionary.

What does volume-weighted average price mean in Yale Podnos’s TOI sale?

The volume-weighted average price of $5.3769 represents the average price across multiple trades, weighted by trade size. The footnote clarifies that individual trades on June 8, 2026 occurred between $5.35 and $5.42 per share within that range.